LYNPARZA is a type of targeted therapy called a PARP inhibitor. It is a prescription oral treatment for adults who have an inherited BRCA mutation (also known as gBRCA or germline BRCA) and HER2-negative metastatic breast cancer that has been treated with chemotherapy, and if HR-positive, treated with hormonal therapy.
LYNPARZA is different from chemotherapy. It takes advantage of DNA damage so that cancer cells can’t get the help they need to survive. LYNPARZA can also affect healthy cells.
In breast cancer, cells in the breast grow out of control.
This growth creates damage that must be repaired in order for the cancer cells to keep growing.
One way to fix this damage is to use PARP, which is an enzyme that has many jobs inside cells—including helping to repair damage.
If PARP is allowed to repair damage, cancer cells can survive, and tumors can continue to grow. That’s why it’s important to try and stop PARP.
That’s where LYNPARZA comes in. LYNPARZA works in 2 ways to help kill cancer cells:
By preventing damage repair and harming cancer cells, LYNPARZA can help stop the tumor from growing.
If you have an inherited BRCA mutation, LYNPARZA can help fight your HER2-negative metastatic breast cancer after previous chemotherapy, and if you’re HR-positive, after previous hormonal therapy. Take the quiz below to put your LYNPARZA knowledge to the test.
HER2=human epidermal growth factor receptor 2; HR=hormone receptor; PARP=poly (ADP-ribose) polymerase.
Cancer cell DNA
Want to test your LYNPARZA knowledge? Take this quick quiz to help you review how LYNPARZA works.
LYNPARZA is a prescription medicine used to treat adults who have:
It is not known if LYNPARZA is safe and effective in children.
LYNPARZA may cause serious side effects, including:
Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.
Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.
Your healthcare provider will do blood tests to check your blood cell counts:
Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.
Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.
How should I take LYNPARZA?
What should I avoid while taking LYNPARZA?
Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.
LYNPARZA may cause serious side effects. The most common side effects of LYNPARZA are:
These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.
You may report side effects related to AstraZeneca products by clicking here.